Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 8.01 (Other Events). FDA Type A meeting minutes received July 14 regarding potential reproxalap NDA resubmission for dry eye disease.
Aldeyra Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA Type A meeting minutes received July 14 regarding potential reproxalap NDA resubmission for dry eye disease
- Aldeyra requested FDA clarification on July 15, signaling unresolved regulatory interpretation
- Planned Type D FDA meeting targeted by end of Q3 2026 to discuss resubmission pathway
- Reproxalap approval timing remains uncertain pending FDA clarification and Type D meeting outcome
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aldeyra Therapeutics, Inc. 8-K filings
Get the next ALDX 8-K as it lands
Follow ALDX for push alerts, or ask the research agent what this filing means.